Brian Mac Grory1, Alex Nackenoff2, Sven Poli3, Martin S Spitzer4, Max Nedelmann5, Benoit Guillon6, Cécile Preterre6, Celia S Chen7, Andrew W Lee8, Shadi Yaghi9, Christoph Stretz1, Idrees Azher1, John Paddock1, Tatiana Bakaeva1,10,11, David M Greer12, Julie G Shulman12, Robert G Kowalski13, Patrick Lavin2,14, Eva Mistry2, Kiersten Espaillat2, Karen Furie1, Howard Kirshner2, Matthew Schrag2. 1. Department of Neurology (B.M.G., C.S., I.A., J.P., T.B., K.F.), Warren Alpert Medical School of Brown University, Providence, RI. 2. Department of Neurology (A.N., P.L., E.M., K.E., H.K., M.S.), Vanderbilt University School of Medicine, Nashville, TN. 3. Department of Neurology with Focus on Neurovascular Diseases, and Hertie Institute for Clinical Brain Research, University Hospital Tübingen, Germany (S.P.). 4. Eye Clinic, University Hospital Hamburg-Eppendorf, Germany (M.S.S.). 5. Department of Neurology, Sana Regio Klinikum, Pinneberg, Germany (M.N.). 6. Department of Neurology, CHU de Nantes - Laennec Nantes, France (B.G., C.P.). 7. Department of Ophthalmology, Flinders Medical Center and Flinders University, Adelaide, Australia (C.S.C.). 8. Department of Neurology, Flinders University and the Calvary Wakefield Hospital, Adelaide, Australia (A.W.L.). 9. Department of Neurology, New York University School of Medicine (S.Y.). 10. Division of Ophthalmology, Department of Surgery (T.B.), Warren Alpert Medical School of Brown University, Providence, RI. 11. Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston (T.B.). 12. Department of Neurology, Boston University School of Medicine, MA (D.M.G., J.G.S.). 13. Department of Neurology, Henry Ford Hospital, Detroit, MI (R.G.K.). 14. Department of Ophthalmology and Visual Sciences (P.L.), Vanderbilt University School of Medicine, Nashville, TN.
Abstract
BACKGROUND AND PURPOSE: Central retinal artery occlusion results in sudden, painless, usually permanent loss of vision in the affected eye. There is no proven, effective treatment to salvage visual acuity and a clear, unmet need for an effective therapy. In this work, we evaluated the efficacy of intravenous tissue-type plasminogen activator (IV alteplase) in a prospective cohort study and an updated systematic review and meta-analysis. METHODS: We enrolled consecutive patients with acute central retinal artery occlusion within 48 hours of symptoms onset and with a visual acuity of <20/200 from January 2009 until May 2019. The primary outcomes were safety and functional visual acuity recovery. We compared rates of visual recovery between those treated with alteplase within 4.5 hours of symptom onset to those who did not receive alteplase (including an analysis restricted to untreated patients presenting within the window for treatment). We incorporated these results into an updated systematic review and patient-level meta-analysis. RESULTS: We enrolled 112 patients, of whom 25 (22.3% of the cohort) were treated with IV alteplase. One patient had an asymptomatic intracerebral hemorrhage after IV alteplase treatment. Forty-four percent of alteplase-treated patients had recovery of visual acuity when treated within 4.5 hours versus 13.1% of those not treated with alteplase (P=0.003) and 11.6% of those presenting within 4 hours who did not receive alteplase (P=0.03). Our updated patient-level meta-analysis of 238 patients included 67 patients treated with alteplase within 4.5 hours since time last known well with a recovery rate of 37.3%. This favorably compares with a 17.7% recovery rate in those without treatment. In linear regression, earlier treatment correlated with a higher rate of visual recovery (P=0.01). CONCLUSIONS: This study showed that the administration of intravenous alteplase within 4.5 hours of symptom onset is associated with a higher likelihood of a favorable visual outcome for acute central retinal artery occlusion. Our results strongly support proceeding to a randomized, placebo-controlled clinical trial.
BACKGROUND AND PURPOSE:Central retinal artery occlusion results in sudden, painless, usually permanent loss of vision in the affected eye. There is no proven, effective treatment to salvage visual acuity and a clear, unmet need for an effective therapy. In this work, we evaluated the efficacy of intravenous tissue-type plasminogen activator (IV alteplase) in a prospective cohort study and an updated systematic review and meta-analysis. METHODS: We enrolled consecutive patients with acute central retinal artery occlusion within 48 hours of symptoms onset and with a visual acuity of <20/200 from January 2009 until May 2019. The primary outcomes were safety and functional visual acuity recovery. We compared rates of visual recovery between those treated with alteplase within 4.5 hours of symptom onset to those who did not receive alteplase (including an analysis restricted to untreated patients presenting within the window for treatment). We incorporated these results into an updated systematic review and patient-level meta-analysis. RESULTS: We enrolled 112 patients, of whom 25 (22.3% of the cohort) were treated with IV alteplase. One patient had an asymptomatic intracerebral hemorrhage after IV alteplase treatment. Forty-four percent of alteplase-treated patients had recovery of visual acuity when treated within 4.5 hours versus 13.1% of those not treated with alteplase (P=0.003) and 11.6% of those presenting within 4 hours who did not receive alteplase (P=0.03). Our updated patient-level meta-analysis of 238 patients included 67 patients treated with alteplase within 4.5 hours since time last known well with a recovery rate of 37.3%. This favorably compares with a 17.7% recovery rate in those without treatment. In linear regression, earlier treatment correlated with a higher rate of visual recovery (P=0.01). CONCLUSIONS: This study showed that the administration of intravenous alteplase within 4.5 hours of symptom onset is associated with a higher likelihood of a favorable visual outcome for acute central retinal artery occlusion. Our results strongly support proceeding to a randomized, placebo-controlled clinical trial.
Authors: Elena Ardila Jurado; Veit Sturm; Florian Brugger; Krassen Nedeltchev; Marcel Arnold; Leo H Bonati; Emmanuel Carrera; Patrik Michel; Carlo W Cereda; Manuel Bolognese; Sylvan Albert; Friedrich Medlin; Christian Berger; Ludwig Schelosky; Susanne Renaud; Julien Niederhauser; Christophe Bonvin; Marie-Luise Mono; Biljana Rodic; Alexander A Tarnutzer; Guido Schwegler; Stephan Salmen; Andreas R Luft; Nils Peters; Jochen Vehoff; Georg Kägi Journal: Front Neurol Date: 2022-05-23 Impact factor: 4.086
Authors: Maria Casagrande; Robert Kromer; Daniel A Wenzel; Sven Poli; Martin S Spitzer; Vasyl Druchkiv; Maximilian Schultheiss; Spyridon Dimopoulos Journal: J Ophthalmol Date: 2021-04-14 Impact factor: 1.909
Authors: Carolin Hoyer; Simon Winzer; Volker Puetz; Kristina Szabo; Egbert Matthé; Ida Heinle; Vesile Sandikci; Darius Nabavi; Michael Platten Journal: Neurol Res Pract Date: 2022-08-01
Authors: Sonja Schönecker; Johannes Wischmann; Dennis C Thunstedt; Katharina Feil; Marc J Mackert; Siegfried Priglinger; Lars Kellert Journal: Life (Basel) Date: 2022-08-22
Authors: Daniel A Wenzel; Sven Poli; Maria Casagrande; Vasyl Druchkiv; Martin S Spitzer; Karl Ulrich Bartz-Schmidt; Carsten Grohmann; Maximilian Schultheiss Journal: Front Med (Lausanne) Date: 2022-07-06